Immuron Limited (AU:IMC)
ASX:IMC
Want to see AU:IMC full AI Analyst Report?
IMC Stock Chart & Stats
AU$0.04
<AU$0.01(3.80%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(3.80%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.10
Previous CloseN/A
Volume128.40K
Average Volume (3M)862.36K
Market Cap
AU$13.07M
Enterprise ValueAU$317.80K
Total Cash (Recent Filing)AU$10.00M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding326,653,600
10 Day Avg. Volume372,599
30 Day Avg. Volume862,359
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.42M
Bulls Say, Bears Say
Bulls Say
Differentiated Therapeutic PlatformImmuron's proprietary oral antibody platform targets gastrointestinal and infectious-disease indications, creating a durable product differentiation. Oral biologics can enable non-invasive dosing and recurring sales; a niche biologic manufacturing capability and marketed/pipeline products support sustained competitive positioning.
Consistent Revenue GrowthPositive top-line growth indicates expanding product uptake or commercialization progress, a foundational sign that the company can scale revenues. If sustained, revenue growth can underpin margin improvement, reduce per-unit R&D overhead and provide a pathway to eventual self-funded operations.
Conservative LeverageVery low indebtedness reduces fixed financial obligations and interest burden, preserving flexibility to fund clinical programs or commercialization from equity or operational cash. Conservative leverage is a durable strength for a biotech that may face irregular funding needs and long development timelines.
Bears Say
Persistent UnprofitabilityOngoing negative operating results show the company is not yet generating sufficient margin from operations. Persistent unprofitability forces reliance on external capital, risks dilution, and challenges long-term sustainability unless commercial margins or scale improve materially.
Negative Operating And Free Cash FlowNegative cash generation constrains the firm's ability to self-fund R&D and commercialization investments, shortens runway, and increases dependency on financing. For a clinical-stage biopharma, sustained negative cash flow elevates execution and financing risk over the medium term.
Small Scale And Financing DependenceA very small headcount and explicit reliance on external financing suggest limited internal commercial and development bandwidth. This raises execution risk, heightens the need for partnerships or raises, and increases the likelihood of dilution or constrained growth if capital access tightens.
Immuron Limited News
IMC FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest share price was AU$0.03 and its highest was AU$0.10 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is AU$13.07M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Aug 28, 2026 which is in 89 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.007.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of -AU$0.007 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went up 14.286%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in AU:IMC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:IMC Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.20%
12-Months-Change
Fundamentals
Return on Equity
-43.95%
Trailing 12-Months
Asset Growth
18.12%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Avecho Biotechnology Limited
―
Anatara Lifesciences Ltd
―
Argenica Therapeutics Ltd
―
EZZ Life Science Holdings Ltd.
―
Biome Australia Ltd
―